Company presentation. June 2017
|
|
- Sharyl Barber
- 5 years ago
- Views:
Transcription
1 1 Company presentation June 2017
2 Clinical stage company focusing on drugs for diseases of the central nervous system, autoimmune diseases and metabolic diseases 3 clinical stage candidates for obesity, metabolic diseases and cocaine addiction Several partnerships with top names in the field World-class research team focused on ion channels with over 25 years of experience Selected partners 2
3 1. Introduction 2. Portfolio I. Clinical stage programs II. Pre-clinical programs 3. Financials and outlook 3
4 Pipeline Product or Target Indication Preclinical research Preclinical development Clinical Phase 1 Clinical Phase 2 Clinical Phase 3 Tesofensine monotherapy Obesity Tesomet Type 2 diabetes Tesomet Prader-Willis syndrome NS2359 Cocaine addiction GABA-A α2/α3 Neuropathic pain Boehringer Ingelheim program Schizophrenia IK Inflammation, IBD Luc Therapeutics program Ataxia Proximagen program Neurological disorders Nicotinic α6 program Parkinson's disease 4
5 Corporate milestones Recent pipeline milestones /2012 Saniona operational 06/2016 U Penn (TRC) initiates Phase 2a study for NS2359 in cocaine addiction 08/2016 Saniona signs partnership with Boehringer Ingelheim for Schizophrenia / Heavily oversubscribed IPO 10/2016 Saniona and Proximagen research collaboration 01/2017 Saniona reports positive top line results from the Tesomet Phase 2a study in type 2 diabetes / Saniona moves to Nasdaq First North Premier 04/2017 Saniona initiates Phase 2a study for Tesomet in Prader-Willi syndrome / Saniona moves to Nasdaq Stockholm Small Cap 04/2017 Saniona obtains research milestone from The Michael J. Fox Foundation for Parkinson's Research 04/2017 Medix receives approval to initiate Phase 3 study in obesity 5 5
6 1. Introduction 2. Portfolio I. Clinical stage programs II. Pre-clinical programs 3. Financials and outlook 6
7 Tesofensine treats Obesity as a CNS disorder Saniona is collaborating with Medix on tesofensine for obesity in Mexico Triple mode of action for unique weight loss Tesofensine is a triple monoamine inhibitor which targets dopamine, serotonin and noradrenaline to stimulate weight loss in obese patients DESCRIPTION Tesofensine is a triple monoamine reuptake inhibitor Food cravings DOPAMINE PLEASURE REWARD CENTER - Humans feel pleasure by eating as it stimulates dopamine - Obese patients crave food and suger due to under stimulation - Tesofensine reduces the craving for food by stimulating the reward center INDICATION (TARGET GEOGRAPHY) Obesity (Mexico) 1 - Prevalence in Mexico: 28.1% Appetite Fat burn SEROTONIN SATIETY CENTER - Humans achieve satiety by eating as it stimulates this center - Obese patients have continuous hunger due to under stimulation - Tesofensine normalizes appetite by stimulating the satiety center NORADRENALINE PATHWAYS - Humans respond to stress by mobilizing energy from fat and increasing the heart rate, both functions are controlled by noradrenaline - Obese patients accumulate fat due to reduced fat burn - Tesofensine increases fat burn, but also heart rate MARKET SIZE The prescription medicine market for obesity in Mexico is around USD 250 million 2 STAGE OF DEVELOPMENT Regulatory approval to start Phase III in 2017 PARTNER 7 (1) World Health Organisation estimate of prevalence for both sexes in (2) Medix estimate.
8 Tesofensine could double weight loss compared to competitors Results at 48 weeks suggest tesofensine could be used as an alternative to surgery Reduction in bodyweight compared to baseline Phase 2b study methodology Randomised, double-blind, placebo controlled trial in five Danish obesity management centers 203 patients were enrolled: - 52 received placebo - 52 assigned to 0.25mg tesofensine group - 50 assigned to 0.50mg tesofensine group - 49 assigned to 1.00mg tesofensine group Energy restricted diet with a daily energy deficit of 300kcal in addition to physical activity of minutes Primary endpoint: percentage change in bodyweight compared to baseline at 24 weeks Phase 2b trial results Placebo 2.0% average reduction 0.25mg tesofensine 6.5% average reduction 0.50mg tesofensine 11.2% average reduction 1.00mg tesofensine 12.6% average reduction Adverse effects similar to placebo with an increase in heart rate compared to baseline Follow up results An open label study was conducted to follow patients for a further 24 weeks after the Phase 2b trial. At 48 weeks patients had lost 14-15% in bodyweight compared to baseline. The results at 48 weeks suggest tesofensine could be competitive to surgery which usually result in 15-20% reduction in bodyweight 8 *Results from competing drugs taken from their respective studies and have been adjusted for their respective placebo results. Results from competing trials are not directly comparable.
9 Placebo controlled weight loss Tesofensine could double weight loss compared to competitors Results at 48 weeks suggest tesofensine could be used as an alternative to surgery Reduction in bodyweight versus competing drugs* Tesofensine 0.5 mg, 48 weeks open label: 14-15% compared to baseline Phase 2b study methodology Randomised, double-blind, placebo controlled trial in five Danish obesity management centers 203 patients were enrolled: - 52 received placebo - 52 assigned to 0.25mg tesofensine group - 50 assigned to 0.50mg tesofensine group - 49 assigned to 1.00mg tesofensine group 10,0% 9,0% 8,0% 7,0% 6,0% 5,0% 5.2% 6.0% 6.6% 9.2% Energy restricted diet with a daily energy deficit of 300kcal in addition to physical activity of minutes Primary endpoint: percentage change in bodyweight compared to baseline at 24 weeks Phase 2b trial results Placebo 2.0% average reduction 0.25mg tesofensine 6.5% average reduction 0.50mg tesofensine 11.2% average reduction 1.00mg tesofensine 12.6% average reduction 4,0% 3,0% 2,0% 1,0% 0,0% 2.4% Xenical, 3x120mg, 4 years 3.1% Belvig, 2x10mg, 1 year Contrave, 2x360/32mg, 56 weeks Victoza, 3mg, 56 weeks Qsymnia, 7.5/46mg, 56 weeks Tesofensine, 0,50mg, 24 weeks Adverse effects similar to placebo with an increase in heart rate compared to baseline Follow up results An open label study was conducted to follow patients for a further 24 weeks after the Phase 2b trial. At 48 weeks patients had lost 14-15% in bodyweight compared to baseline. The results at 48 weeks suggest tesofensine could be competitive to surgery which usually result in 15-20% reduction in bodyweight 9 *Results from competing drugs taken from their respective studies and have been adjusted for their respective placebo results. Results from competing trials are not directly comparable.
10 Medix Phase 3 study Medix to initiate Phase 3 in 2017 and could potentially be on the market before 2020 Randomised, double-blind, placebo controlled trial in Mexican population 372 patients to be enrolled: 124 will receive placebo 124 will receive 0.25mg tesofensine 124 will receive 0.50mg tesofensine All patients are prescribed an energy restricted diet with a daily energy of 1,500-2,000 kcal in addition to a physical activity of minutes Primary endpoint: percentage change in bodyweight compared to baseline at 24 weeks Secondary endpoints include: proportions of patients achieving a weight loss of more than 5 and 10 percent respectively, metabolic including glycaemic endpoints, quality of life. 10
11 EFFECT INDICATIONS COMPOSITION Tesomet - Potential blockbuster drug with orphan drug prospects Tesomet s mechanism of action creates multiple opportunities within metabolic diseases Tesomet Indications and treatment effects Potential best-in-class profile combining unmatched weight loss with a benign side effect profile for the treatment of weight related metabolic diseases DESCRIPTION Tesomet is a fix-dosed combination of tesofensine and metoprolol TESOFENSINE Effective weight loss drug TYPE 2 DIABETES PRADER WILLI METOPROLOL Beta blocker to control increased heart rate FATTY LIVER (NASH) INDICATIONS Type 2 diabetes 1 - Global prevalence: ~370 million Prader Willi 2 - Global prevalence ~0.4million Fatty liver (NASH) 3 - US prevalence +10 million Chronic condition characterized by elevated blood glucose Rare genetic disorder which among other things causes a chronic feeling of hunger leading to excessive eating Common disease characterised by a build up of fat in the liver potentially leading to liver damage MARKET SIZE Type 2 diabetes 4 Prader Willi Fatty liver USD 23bn NA NA Reduction of fat in the liver leading to normalisation of diabetic symptoms and long term remission Reduction in the chronic feeling of hunger to normal levels Reduction of fat build-up in the liver allowing a reversal of disease progression STAGE OF DEVELOPMENT Phase IIa recruitment completed PROPRIETARY PROJECT 11 (1) Estimate based on International Diabetes Federation s total estimate of diabetics in the world in 2015 and the average estimate of split between type 1 and 2 diabetes based on: Tuomilehto J. The emerging global epidemic of type 1 diabetes. Curr Diab Rep 2013; 13: and Centers for Disease Control and Prevention, National diabetes statistics report: estimates of diabetes and its burden in the United States, Atlanta, GA: US Department of Health and Human Services, 2014 (2) Butler MG, Hanchett JM, Thompson T. Clinical findings and natural history of Prader-Willi syndrome. In: Management of Prader-willi Syndrome, Butler MG, Lee PDK, Whitman BY (Eds), Springer, New York 2006 (3) G. Vernon; A. Baranova; Z. M. Younossi, The Epidemiology and Natural History of Non-alcoholic Fatty Liver Disease and Non-alcoholic Steatohepatitis in Adults ( (4) Datamonitor, 2014.
12 Retrospective analysis on pre-diabetics in TIPO-1 study Tesofensine induces weight loss and reduces HbA1c in overweight pre-diabetics Pre-diabetics obtain significant weight loss Pre-diabetics obtain normalization of HbA1C 12
13 Tesomet Phase 2a study to prove efficacy and safety Result: Tesomet neutralize increase in heart rate and maintain extraordinary weight loss Phase 2a high level development plan Tesomet meets primary endpoint 60 type 2 diabetes patients with two arms: placebo versus Tesomet Heart rate reduced with of 4.3 bpm (p= versus placebo) 3 months treatment No diet nor exercise introduced Primary endpoint Demonstrate that Metoprolol can counteract tesofensine s heart rate effects Tesomet reduce body weight, blood pressure and liver fat Body weight reduced with 3.5 kg (3.5%) (p< versus placebo) Waist circumference reduced with 2.29 cm (p<0.01 versus placebo) Secondary endpoints Numerical reduction in blood pressure Systolic reduced by 3.1 mmhg (p=0.152) ENDPOINT RELEVANT INDICATION Diastolic reduced by 2.2 mmhg (p=0.138) Sustained efficacy of Tesomet on weight loss Type 2 diabetes, Prader Willi, Fatty liver Numerical reduction in liver fat content of 8.3% whereas placebo Effect on liver fat Fatty liver and type 2 diabetes increased with 11.1% (p=0.0625) Effect on glycemic endpoints Type 2 diabetes Glycemic secondary efficacy endpoints not significantly reduced in this rather short 12-week study. 13
14 Additional indication added following positive Phase 2a results Saniona initiated a Phase 2a trial in Prader Willi Syndrome in Q Prader Willi A rare genetic disorder Chronic feeling of extreme hunger Excessive eating and life-threatening obesity Incidence is 1 in 15,000 live births No cure available today Expensive for society and burdensome for affected families Limited numbers of ongoing programs in the pipeline Small Phase 2a study initiated in April 2017 Exploratory randomized, double-blind, placebocontrolled 12 weeks study in patients 3:2 - randomization Tesomet (tesofensine 0.5 mg + metoprolol 50 mg) Placebo Split in two parts with safety evaluation First part: adult patients Second part: adolescents Results expected one year from initiation Tesomet A promising candidate for PWS Tesomet could provide substantial benefits to patients Potential for orphan drug status, breakthrough designation and expedited review Relatively small and manageable clinical program: - Small Proof of Concept study may serve as Phase 2 (Zafgen n=17) - Phase 3 trials likely to be a few hundred patients (Zafgen n=108, 6 months) 14
15 Next step for Tesomet Prepare for long term Phase 2b and Phase 3 studies by Saniona or together with a partner Increase data package in order to enable long term studies with combination product Long term preclinical studies on combination Phase 1 clinical study on the fixed dose combination pill Indications and patient population for consideration Type 2 diabetes or subgroup of type 2 diabetes patients (e.g. maximum x years from diagnosis) Obesity or obese diabetics Binge eating, Nash Prader Willi (potential phase 3) Major Phase 2b design elements Multi arm study 6 months study Diet and Exercise 15
16 Dopamine levels NS2359 Potential first drug for cocaine addiction Phase IIa study initiated in June 2016 at the University of Pennsylvania NS2359 blunts highs and subsequent lows associated with cocaine NS2359 administered together with cocaine NS2359 normalizes dopamine levels in addicts and blunts highs and lows after cocaine Speed of increase and level of dopamine causes the feeling of euphoria NS cocaine Cocaine DESCRIPTION NS2359 is a triple monoamine reuptake inhibitor which blocks the reuptake of dopamine, norepinephrine and serotonin INDICATION Cocaine addiction million cocaine dependents in the US Normal Speed of drop in dopamine causes the feeling of a crash MARKET SIZE The global market for first class treatment for cocaine dependence is estimated at USD 1.2bn 2 Addict Time STAGE OF DEVELOPMENT Phase IIa initiated in 2016 Withdrawl symptoms Cravings Feeling of Euphoria PARTNER 16 (1) National Survey on Drug Use and Health. (2) National Institute on Drug Abuse (NIDA).
17 Phase IIa study being conducted at world class institution University of Pennsylvania TRC is among the top sites for clinical trials in drug addiction Phase I data supports NS2359 s efficacy Phase IIa high level development plan Phase I data in 24 psychostimulant cocaine users shows NS2359 reduces the attractiveness of cocaine to addicts in multiple factors 80 cocaine addicts with two arms: placebo versus NS weeks treatment "Amount you would pay" 39% 100% Primary endpoint "Like to use" 32% 100% Abstinence from cocaine during the last 2 weeks of treatment "Feeling stimulated" 58% 100% Secondary endpoints "Desire" 36% 100% Reduce craving for cocaine and withdraw symptoms Reduce amount of alcohol consumption "Drug liking" 23% 100% Reduce smoking Improved cognitive ability "Feeling high" 53% 100% Trial site 0% 20% 40% 60% 80% 100% Cocaine NS cocaine In addition to normalising the heart rate Heart rate
18 1. Introduction 2. Portfolio I. Clinical stage programs II. Pre-clinical programs 3. Financials and outlook 18
19 Boehringer deal new preclinical collaboration Further validation of Saniona s partnering approach FOCUS Develop novel compounds for the treatment of schizophrenia DRUG TARGET Unique Saniona ion channel research program FINANCIALS Saniona will receive: - EUR 5m (SEK ~ 47.4m) in upfront payment - Research funding - Up to EUR 90m (SEK ~853m) in milestone payments - Royalties on worldwide net sales of any resulting products under the collaboration Active preclinical programs Program Indication Partner Boehringer GABAA α2/α3 IK program Ataxion Proximagen Nicotinic α6 Schizophrenia Neuropathic pain Inflammation, IBD Ataxia Neurological disorders Parkinson s disease Added 29 August
20 Pipeline financing and commercial rights distribution Saniona commercial rights GABAA α2/α3 Pain IK program IBD A free ride NS2359 cocaine addiction Saniona finance Tesomet metabolic Tesomet Prader-Willi Tesomet obesity Tesofensine obesity 3 rd party finance Risk sharing 3 rd party commercial rights Clinical stage programs Pre-clinical programs 20
21 1. Introduction 2. Portfolio I. Clinical stage programs II. Pre-clinical programs 3. Financials and outlook 21
22 Strategy and financing Focus internal investments on most advanced programs Evaluate potential of Tesomet in various indications and preparing for late stage clinical trials: - Phase 2 in T2D a disruptive concept in a very large market - Prader Willis an orphan metabolic disorder with no treatment today - Binge eating a relative large CNS based disorder with poor treatment options today - NASH (fatty liver) the next projected metabolic syndrome epidemic Select and develop one additional clinical candidate Partners pave the way for two clinical programs which could reach the market within 3-5 years Medix conducts Phase 3 for tesofensine in obesity to obtain market approval in the first 2 countries University of Penn conducts Proof of Concept on NS2359 for cocaine addictions based on external grants Funded research engine secures long term value and financial support to internal activities Research collaborations create long term value as projects develop to clinical stage Research collaborations also provide funding for internal activities until market approval - Operational costs - Investments in internal pipeline 22
23 Financial position Income statement MSEK Acummulated Net sales Operating expenses Operating profit/loss Financial items Tax on net profit Profit/loss Other comprehensive income Total comprehensive income Balance sheet MSEK Dec-16 Dec-15 Dec-14 Dec-13 Dec-12 Non-current assets Current receivables Cash and cash equivalent Total assets Equity Total liabilities Total equity and liabilities Cash flows MSEK Acummulated Operating activities Investing activities Financing activities Cash flow
24 Ambitions for 2017 Pipeline ambitions Current status Report top-line data on Tesomet Phase 2a Initiate a Phase 2a study on Tesomet for Prader-Willi syndrome Initiate Phase 3 for tesofensine in Mexico together with Medix Selection of clinical candidate and initiation of preclinical development for at least one of the current drug discovery programs January April + Regulatory approval, April 2017 Business development ambitions Additional partnering on clinical assets Collaboration or spin-outs on other programs and platform 1 Spin-out, May 2017 Corporate ambitions List Saniona on Nasdaq Stockholm Listed in June
25 Summary 1 Clinical stage company with 3 programs in Phase 2 clinical trials - Tesomet for T2D financed by Saniona - Tesomet for Prader-Willi financed by Saniona - NS2359 for cocaine addiction based on grants 2 New partnerships with significant potential - 4 new partnerships - Spin-out of Initiator Pharma and distribution of shares according to Lex ASEA - Spin-out of Scandion Oncology 3 Many future potential inflection points - Medix initiates Phase 3 for tesofensine in obesity - Selection of clinical candidate for internal development - Safety read out and results for Prader Willi study as well as future plans for Tesomet 25 - Interim data for NS2359 in cocaine addiction - World class research team and several programs for partnering or spin-outs
SANIONA COMPANY PRESENTATION
SANIONA COMPANY PRESENTATION MARCH, 2016 March 2016 1 THE SANIONA WAY Low burn rate without compromising on high ambitions Top class science World-class research team focused on ion channels CNS, pain,
More informationMay 15th, Med Sedemera på Aktietorget - til Nasdaq Smallcap på 4 år
1 May 15th, 2018 Med Sedemera på Aktietorget - til Nasdaq Smallcap på 4 år Saniona: Reduced risk high upside potential Reduced risk Very broad pipeline Risk mitigated late stage programs Many partnerships
More informationCompany Presentation. February 2019
1 Company Presentation February 2019 FORWARD LOOKING STATMENTS This presentation contains forward-looking statements that provide Saniona s expectations or forecasts of future events such as new product
More informationCompany Presentation. January 2019
1 Company Presentation January 2019 FORWARD LOOKING STATMENTS This presentation contains forward-looking statements that provide Saniona s expectations or forecasts of future events such as new product
More informationCorporate Presentation
Corporate Presentation March 2018 Safe Harbor Statement Factors Affecting Future Performance This presentation contains "forward-looking" statements within the meaning of the United States Private Securities
More informationCorporate Presentation Asia Investment Series March 2018
Corporate Presentation Asia Investment Series March 2018 Safe Harbor Statement Factors Affecting Future Performance This presentation contains "forward-looking" statements within the meaning of the United
More informationZealand Pharma A/S Interim report for Q (un-audited)
Company Announcement No. 12/2012 (un-audited) Net profit for the quarter of DKK 66 (EUR 9) million Important pipeline progress, and revenue from milestone payments of DKK 120 (EUR 16) million Cash and
More informationSupernus Pharmaceuticals
Supernus Pharmaceuticals Jefferies 2016 Healthcare Conference May 2016 1 Safe Harbor Statement This presentation and other matters discussed today or answers that may be given to questions asked include
More informationAnti-IL-33 (ANB020) Program
Anti-IL-33 (ANB020) Program Phase 2a Peanut Allergy Clinical Trial Interim Data Update March 26 th 2018 NASDAQ: ANAB Safe Harbor Statement This presentation and the accompanying oral presentation contain
More informationInterim Report 1 January September 2017
2014-01-01 2014-12 Interim Report 1 January 2017 30 September 2017 Cantargia AB 556791-6019 Cantargia refers to Cantargia AB (publ), corporate ID number 556791-6019. Clinical trial initiated Highlights
More informationPresentation to AGM 9 November Deborah Rathjen CEO & Managing Director
Presentation to AGM 9 November 2011 Deborah Rathjen CEO & Managing Director Safe Harbor Statement Factors Affecting Future Performance This presentation contains "forward looking" statements within the
More informationMerrill Lynch's Global Pharmaceutical, Biotechnology, and Medical Device Conference. February 7, 2007
Merrill Lynch's Global Pharmaceutical, Biotechnology, and Medical Device Conference February 7, 2007 Information related to forward-looking statements This presentation includes forward-looking statements
More informationEmisphere Technologies, Inc. Announces 2008 Second Quarter Financial Results
August 11, 2008 Emisphere Technologies, Inc. Announces 2008 Second Quarter Financial Results Conference Call/Webcast to be Held Monday, August 11 at 10:00 AM EDT CEDAR KNOLLS, N.J., Aug 11, 2008 /PRNewswire-FirstCall
More informationCalliditas Therapeutics Q2 Report Webcast August 16, 2018, 10:00 Presenters: Renée Aguiar-Lucander, CEO Fredrik Johansson, CFO
Calliditas Therapeutics Q2 Report 2018 Webcast August 16, 2018, 10:00 Presenters: Renée Aguiar-Lucander, CEO Fredrik Johansson, CFO Disclaimer Important information This presentation may contain certain
More informationCorporate Overview June 2014 Jefferies Healthcare Conference NASDAQ: GLYC
Corporate Overview June 2014 Jefferies Healthcare Conference NASDAQ: GLYC Forward-Looking Statements To the extent that statements contained in this presentation are not descriptions of historical facts
More informationSupernus Pharmaceuticals
Supernus Pharmaceuticals Investor Presentation March 2017 1 Safe Harbor Statement This presentation and other matters discussed today or answers that may be given to questions asked include forward-looking
More informationFinancial results in line with expectations and important progress of the pipeline
Company Announcement - No. 37 / 2015 Zealand Interim report for H1 2015 (un-audited) Financial results in line with expectations and important progress of the pipeline Growing lixisenatide (Lyxumia ) royalty
More informationObsEva Reports First Quarter 2018 Financial Results and Provides Business Update
ObsEva Reports First Quarter 2018 Financial Results and Provides Business Update -Key First Quarter 2018 Clinical Milestones Achieved Patient randomization completed in Phase 2b EDELWEISS trial of OBE2109
More informationZealand announces full year results in line with guidance and release of its Annual Report for 2015
Company announcement No. 5 / 2016 Zealand announces full year results in line with guidance and release of its Annual Report for 2015 2015 was a transitional year for Zealand with considerable business
More informationASCEND Phase 2 Trial of AXS-05 in MDD Topline Results Conference Call
NASDAQ: AXSM ASCEND Phase 2 Trial of in MDD Topline Results Conference Call January 7, 2019 Overview in MDD ASCEND Phase 2 Trial Topline Results Introduction Mark Jacobson, Senior Vice President, Operations
More informationFebruary 23, Q4 and Year-End 2016 Financial Results
February 23, 2017 Q4 and Year-End 2016 Financial Results 2 RETHINKING CNS Agenda Today s Speakers Paul Cox, Senior Director, Investor Relations Jeff Jonas, M.D., Chief Executive Officer Jim Doherty, Ph.D.,
More informationEvotec AG FY 2006 Results Presentation, 29 March Translating Innovation into Results
Evotec AG FY 2006 Results Presentation, 29 March 2007 Translating Innovation into Results Agenda 01 Highlights 2006 02 Pipeline 03 Collaborations 04 FY 2006 Results 05 Outlook 2007 3/28/2007 Folie 2 01
More informationDynavax Corporate Presentation
Dynavax Corporate Presentation Forward-Looking Statements This presentation contains forward-looking statements, including statements regarding our HEPLISAV-B TM regulatory submissions, product profile,
More informationZealand interim report for the first nine months of 2015 (un-audited): Financial results on target with significant pipeline progress
Company Announcement No. 48 / 2015 Zealand interim report for the first nine months of 2015 (un-audited): Financial results on target with significant pipeline progress Lyxumia royalties and milestone
More informationCATALYST PHARMACEUTICAL PARTNERS, INC. Innovative Biotech Could Be Sitting On Two Blockbuster Drugs
CATALYST PHARMACEUTICAL PARTNERS, INC. Innovative Biotech Could Be Sitting On Two Blockbuster Drugs Rob Goldman May 4, 2010 rob@goldmanresearch.com CATALYST PHARMACEUTICAL PARTNERS, INC. (OTC CPRX - $1.41)
More informationNovember 2, Q Financial Results
November 2, 2017 Q3 2017 Financial Results Agenda Today s Speakers Paul Cox, Senior Director, Investor Relations Jeff Jonas, M.D., Chief Executive Officer Steve Kanes, M.D., Ph.D., Chief Medical Officer
More informationPhase 3 investigation of aprocitentan for resistant hypertension management. Investor Webcast June 2018
Phase 3 investigation of aprocitentan for resistant hypertension management Investor Webcast June 2018 The following information contains certain forward-looking statements, relating to the company s business,
More informationHALOZYME REPORTS SECOND QUARTER 2018 RESULTS
Contacts: Robert H. Uhl Managing Director Westwicke Partners, LLC 858-356-5932 robert.uhl@westwicke.com Laurie Stelzer 858-704-8222 ir@halozyme.com FOR IMMEDIATE RELEASE HALOZYME REPORTS SECOND QUARTER
More informationBNC210 Update BNO (Australia: ASX) BNOEF (USA: OTCQX) 18 February 2019 Central Nervous System (CNS)
BNC210 Update BNO (Australia: ASX) BNOEF (USA: OTCQX) 18 February 2019 Central Nervous System (CNS) Safe Harbor Statement Factors Affecting Future Performance This presentation contains "forward-looking"
More informationWe want to save patients with severe cancer and autoimmune diseases Clinical investigations with our lead antibody CAN04 to our proprietary target
We want to save patients with severe cancer and autoimmune diseases Clinical investigations with our lead antibody CAN04 to our proprietary target Göran Forsberg, CEO 1 Safe Harbour Statement The following
More informationAugust 7, Q Financial Results
August 7, 2018 Q2 2018 Financial Results 1 Agenda Today s Speakers Paul Cox, Senior Director, Investor Relations Jeff Jonas, M.D., Chief Executive Officer Steve Kanes, M.D., Ph.D., Chief Medical Officer
More informationCEO & MANAGING DIRECTOR S REPORT TO SHAREHOLDERS
ASX ANNOUNCEMENT 15 November 2017 ABN 53 075 582 740 CEO & MANAGING DIRECTOR S REPORT TO SHAREHOLDERS I am delighted to report that the past year has been a particularly strong one for the Company with
More informationObsEva Reports Third Quarter 2017 Financial Results and Provides Business Update
ObsEva Reports Third Quarter 2017 Financial Results and Provides Business Update - All Three Development Compounds Progressing with Key Clinical Milestones Over the Next 12 Months - Geneva, Switzerland
More informationINTERIM MANAGEMENT STATEMENT Q3 2017
INTERIM MANAGEMENT STATEMENT Q3 2017 Significant progress across all clinical programs New pre-clinical immunooncology data to be presented during R&D Day in New York Research & Development highlights:
More informationBusiness Update & Financial Results for Q1 2018
Business Update & Financial Results for Q1 2018 May 15, 2018 Disclaimer The statements made in this presentation may include forward-looking statements regarding the future operations of ERYTECH Pharma
More informationPhotoCure ASA Presentation First quarter 2005 May 3, 2005
PhotoCure ASA Presentation First quarter 2005 May 3, 2005 Obtaining milestones and building value Hexvix Approval in 27 EU/EEA countries, working on national approvals Ongoing phase III study for extended
More informationInterim report Second quarter 2017 and subsequent events (Unaudited)
SERODUS ASA Interim report Second quarter 2017 and subsequent events (Unaudited) August 2017 2017-08-15 Q2-2017 report ABOUT SERODUS Serodus is a private biotech company with a focus on diabetic comorbidities
More informationSunesis Pharmaceuticals Reports Second Quarter 2011 Financial Results
Investor and Media Inquiries: David Pitts Argot Partners 212-600-1902 Eric Bjerkholt Sunesis Pharmaceuticals Inc. 650-266-3717 Sunesis Pharmaceuticals Reports Second Quarter 2011 Financial Results SOUTH
More informationOncology Therapeutics without Compromise APRIL 2011
Oncology Therapeutics without Compromise APRIL 2011 Forward Looking Statements This presentation contains forward-looking statements that involve substantial risks and uncertainties, including among other
More informationBioCryst Pharmaceuticals
BioCryst Pharmaceuticals Jefferies 2010 Global Life Sciences Conference New York Stuart Grant Senior Vice President & Chief Financial Officer Rob Bennett Executive Director, Investor Relations & Business
More informationA world leader in allergy immunotherapy. Jefferies Global Healthcare Conference, London : 19 November 2014 : Flemming Pedersen, CFO & EVP
A world leader in allergy immunotherapy ALK at a glance Leading allergy immunotherapy (AIT) specialist AIT: Treats the root cause of allergy Products in all areas of AIT ALK has 33% of the global AIT market
More informationWe want to save patients with severe cancer and autoimmune diseases Clinical investigations with our lead antibody CAN04 to our proprietary target
We want to save patients with severe cancer and autoimmune diseases Clinical investigations with our lead antibody CAN04 to our proprietary target Göran Forsberg, CEO 1 Safe Harbour Statement The following
More informationMOLOGEN AG. Our research for you. Annual Results Analysts Call March 21, 2013
Our research for you. Annual Results 2012 Analysts Call March 21, 2013 Disclaimer Certain statements in this communication contain formulations or terms referring to the future or future developments,
More informationAradigm Corporation. A respiratory specialty pharmaceutical company fulfilling unmet needs in pulmonary medicine (ARDM) February 2008
Aradigm Corporation A respiratory specialty pharmaceutical company fulfilling unmet needs in pulmonary medicine (ARDM) February 2008 Safe Harbor Statement This presentation contains forward-looking statements
More informationMemory Pharmaceuticals Establishes Plans for Clinical Program for MEM 3454 in Schizophrenia. -Broadens Roche Nicotinic Alpha-7 Alliance-
Memory Pharmaceuticals Establishes Plans for Clinical Program for MEM 3454 in Schizophrenia -Broadens Roche Nicotinic Alpha-7 Alliance- -Secures Additional $5M Debt Financing to Support Phase 2a Trial-
More informationAddex Therapeutics. Partnership in Addiction, Valuation Increased. Research Note.
Research Note Addex Therapeutics Partnership in Addiction, Valuation Increased Chief Research Analyst Marcel Wijma MSc +1 (917) 460 6185 (US) +31 (6) 1848 4204 (NL) m.wijma@leeuwenhoeck.com http://www.leeuwenhoeck.com
More informationAstraZeneca to Acquire Bristol- Myers Squibb Share of Global Diabetes Alliance. Becoming Global Leaders In Diabetes
AstraZeneca to Acquire Bristol- Myers Squibb Share of Global Diabetes Alliance Becoming Global Leaders In Diabetes 19th December 2013 Cautionary Statement Regarding Forward-Looking Statements In order,
More informationGROWING THE BUSINESS WITH 2015 AS A CATALYST YEAR
ZEALAND GROWING THE BUSINESS WITH 2015 AS A CATALYST YEAR US Roadshow June 2015 ZEALAND PHARMA DISCLAIMER This presentation does not constitute or form part of and should not be construed as, an offer
More informationImprove life for cancer patients through transformative drugs
March 21, 2017 Improve life for cancer patients through transformative drugs R&D dedicated company focused on oncology Scientific platforms consistently delivering well-differentiated new projects Deep
More informationDeveloping & Commercializing Targeted Small Molecule Drugs in Cancer
Developing & Commercializing Targeted Small Molecule Drugs in Cancer SAFE HARBOR STATEMENT 2 Forward-looking statements made in the course of this presentation are made pursuant to the safe harbor provisions
More informationAVEO Oncology Announces Strategic Restructuring. AVEO to Host Conference Call Wednesday, June 5 at 8:30 a.m. ET
NEWS RELEASE FOR IMMEDIATE RELEASE AVEO Oncology Announces Strategic Restructuring AVEO to Host Conference Call Wednesday, June 5 at 8:30 a.m. ET CAMBRIDGE, Mass., June 4, 2013 AVEO Oncology (NASDAQ: AVEO)
More informationMerrill Lynch Healthcare Conference New York
Merrill Lynch Healthcare Conference New York Matthew Emmens Chief Executive Officer February 3, 2004 A Strategic Review Today and Beyond Clear Strengths Highly successful business model Strong pipeline
More informationHIGH CLINICAL ACCEPTANCE OF METVIX PDT
HIGH CLINICAL ACCEPTANCE OF METVIX PDT PhotoCure ASA Second Quarter Report 2002 Highlights: Marketing of Metvix PDT in Europe Progressing as Planned Positive Phase III Clinical Results in the Treatment
More informationMedivir Q Conference call 18 February, 2016
Medivir Q4-2015 Conference call 18 February, 2016 Niklas Prager CEO Ola Burmark CFO Richard Bethell EVP R&D A research-based pharmaceutical company with focus on infectious diseases and oncology Q4 Highlights
More informationObsEva Reports Third Quarter 2018 Financial Results and Provides Business Update
ObsEva Reports Third Quarter 2018 Financial Results and Provides Business Update IMPLANT 4 trial of nolasiban in IVF starting in Q4 2018, European MAA filing expected late 2019 24-week data from Phase
More informationInvestor Presentation
Investor Presentation February 2018 2 FORWARD-LOOKING INFORMATION The following presentation contains statements that are considered forward-looking information ( FLI ) within the meaning of securities
More informationZacks Small-Cap Research
Zacks Small-Cap Research Sponsored Impartial - Comprehensive August 29, 2018 David Bautz, PhD 312-265-9471 dbautz@zacks.com scr.zacks.com 10 S. Riverside Plaza, Chicago, IL 60606 Opiant Pharmaceuticals,
More informationTitan Pharmaceuticals: Highlights
Corporate Presentation January 2013 1 Safe Harbor The presentation may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities
More informationSmall-Cap Research. Oramed Pharmaceuticals (ORMP-NASDAQ) ORMP: Zacks Company Report OUTLOOK
Small-Cap Research April 21, 2017 Grant Zeng, CFA 312-265-9421 gzeng@zacks.com scr.zacks.com 10 S. Riverside Plaza, Chicago, IL 60606 Oramed Pharmaceuticals (ORMP-NASDAQ) ORMP: Zacks Company Report ORMP:
More informationDepression Rising (Again): Turning the Corner in Psychiatry s Most Burdensome Disorder
Depression Rising (Again): Turning the Corner in Psychiatry s Most Burdensome Disorder Joel Sandler, Ph.D. Associate Principal, Defined Health Harry Tracy, Ph.D. Founder and President, NI Research Roger
More informationProprietary Products Update. Markku Huhta-Koivisto, SVP Proprietary Products
Proprietary Products Update Markku Huhta-Koivisto, SVP Proprietary Products Orion s partnering strategy is based on profitable growth and increased shareholder value whilst keeping business risk under
More informationBioArctic announces positive topline results of BAN2401 Phase 2b at 18 months in early Alzheimer s Disease
Press release BioArctic announces positive topline results of BAN2401 Phase 2b at 18 months in early Alzheimer s Disease The full 18 month analysis of the 856 patient BAN2401 Phase 2b clinical study in
More informationREATA PHARMACEUTICALS, INC. ANNOUNCES SECOND QUARTER 2018 FINANCIAL RESULTS AND AN UPDATE ON DEVELOPMENT PROGRAMS
REATA PHARMACEUTICALS, INC. ANNOUNCES SECOND QUARTER 2018 FINANCIAL RESULTS AND AN UPDATE ON DEVELOPMENT PROGRAMS IRVING, Texas August 8, 2018 Reata Pharmaceuticals, Inc. (Nasdaq: RETA), a clinical-stage
More informationZafgen PWS Clinical Trial Program Overview. November 16, 2014
Zafgen PWS Clinical Trial Program Overview November 16, 2014 2 Disclaimers Forward Looking Statements These slides and the accompanying oral presentation contain forward-looking statements and information.
More informationIMMUNOMEDICS, INC. Advanced Antibody-Based Therapeutics. Jefferies 2014 Global Healthcare Conference Cynthia L. Sullivan, President and CEO
IMMUNOMEDICS, INC. Advanced Antibody-Based Therapeutics Oncology Autoimmune Diseases Jefferies 2014 Global Healthcare Conference Cynthia L. Sullivan, President and CEO Forward-Looking Statements This presentation,
More informationTELECONFERENCE FY February 2015
TELECONFERENCE FY 2014 5 February 2015 Company disclaimer This presentation contains forward-looking statements that provide our expectations or forecasts of future events such as new product introductions,
More informationscr.zacks.com 111 North Canal Street, Chicago, IL (DARA-NASDAQ) OUTLOOK ZACKS ESTIMATES
Small-Cap Research November 18, 2011 Jason Napodano, CFA 312-265-9421 jnapodano@zacks.com scr.zacks.com 111 North Canal Street, Chicago, IL 60606 DARA BioSciences, Inc. (DARA-NASDAQ) DARA: Pipeline Moving
More informationTitan Pharmaceuticals Overview
Corporate Presentation July 2014 1 Safe Harbor The presentation may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities
More informationInovio Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter)
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event
More informationWntResearch. 100% one-week return? 16 October 2017 PRICE EXPECTATIONS INVESTMENT CASE PRICE TRIGGERS PRICE 12 MONTHS COMPANY PROFILE
Occasion: Initial coverage +37% +71% 100% one-week return? s share price has dropped by more than 50% since the announcement of the current and ongoing public offering. In theory the share price should
More informationD IA M Y D M E D ICAL
ANNUAL REPORT 09/10 TABLE OF CONTENTS The year in brief... 2 Diamyd in brief... 3 CEO comments... 4 Diamyd s business model... 6 The Diamyd story... 10 Business area Diabetes... 12 Business area Pain...
More informationInvestor Overview. March 2019
Investor Overview March 2019 Forward-Looking Statement These slides and the accompanying oral presentation contain forward-looking statements and information. The use of words such as may, might, will,
More informationNewLink Genetics Corporation Provides Operational Update and Reports Second Quarter 2015 Financial Results
July 31, 2015 NewLink Genetics Corporation Provides Operational Update and Reports Second Quarter 2015 Financial Results -Management to Host Conference Call Today at 8:30 a.m. ET- AMES, Iowa, July 31,
More informationPhotocure ASA Executing the Strategy
Photocure ASA Executing the Strategy NOVEMBER 2012 ERIK DAHL, CFO KATHLEEN DEARDORFF, COO Disclaimer The information included in this Presentation contains certain forward-looking statements that address
More informationMOLOGEN AG. Pioneering Immune Therapy. Q1 Results 2014 Conference Call. Dr. Matthias Schroff, CEO
Pioneering Immune Therapy Q1 Results 2014 Conference Call Dr. Matthias Schroff, CEO Berlin, 14 May 2014 V1-6 Disclaimer Certain statements in this presentation contain formulations or terms referring to
More informationTELECONFERENCE Q August 2015
TELECONFERENCE Q2 2015 19 August 2015 Company disclaimer This presentation contains forward-looking statements that provide our expectations or forecasts of future events such as new product introductions,
More informationNektar Investor & Analyst Call. Nektar & z Bristol-Myers Squibb Collaboration. February 14, 2018
Nektar Investor & Analyst Call Nektar & z Bristol-Myers Squibb Collaboration February 14, 2018 This presentation includes forward-looking statements regarding Nektar s proprietary drug candidates, the
More informationForward Looking Statements
Slide title Forward Looking Statements This presentation may contain forward looking statements with respect to the financial condition, results and business achievements/performance of Biotron Limited
More informationForward Looking Statements
Therapeutic products for respiratory diseases September 2008 Forward Looking Statements This presentation may contain forward-looking statements that are based on management s current expectations and
More informationCorporate Presentation Rodman & Renshaw Deborah Rathjen CEO & Managing Director
Corporate Presentation Rodman & Renshaw Deborah Rathjen CEO & Managing Director September 2017 Safe Harbor Statement Factors Affecting Future Performance This presentation contains "forward-looking" statements
More informationLION. Corporate Presentation June 2016 BIOTECHNOLOGIES. Leadership & Innovation in Oncology
LION BIOTECHNOLOGIES Leadership & Innovation in Oncology Corporate Presentation June 2016 Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the Private
More informationMay 9, Q Financial Results
May 9, 2017 Q1 2017 Financial Results Agenda Today s Speakers Paul Cox, Senior Director, Investor Relations Jeff Jonas, M.D., Chief Executive Officer Steve Kanes, M.D., Ph.D., Chief Medical Officer Kimi
More informationQUARTERLY REPORT 1. September 2016 November Diamyd Medical AB (publ), Fiscal year 2016/2017
QUARTERLY REPORT 1 September November Diamyd Medical AB (publ), Fiscal year /2017 Reporting period, September 1, November 30, Net result amounted to MSEK -4.3 (-4.3) Net result per share amounted to SEK
More informationTwo-stage study designed to evaluate tolerability and efficacy of pracinostat combined with azacitidine in patients with high and very high risk MDS
Helsinn Group and MEI Pharma Announce First Patient Dosed in Phase 2 Dose-Optimization Study of Pracinostat and Azacitidine in Myelodysplastic Syndrome Two-stage study designed to evaluate tolerability
More informationWe want to save patients with severe cancer and autoimmune diseases Entering clinical phase with our lead antibody CAN04 to our proprietary target
We want to save patients with severe cancer and autoimmune diseases Entering clinical phase with our lead antibody CAN04 to our proprietary target Göran Forsberg, CEO 1 Safe Harbour Statement The following
More informationMOLOGEN AG. Our research for you. German Equity Forum November 2012
Our research for you. German Equity Forum 12-14 November 2012 Disclaimer Certain statements in this communication contain formulations or terms referring to the future or future developments, as well as
More informationCorporate Presentation October 2018 Nasdaq: ADXS
Innovations in Immuno-Oncology Corporate Presentation October 2018 Nasdaq: ADXS Forward-Looking Statements This presentation contains forward-looking statements, including, but not limited to, statements
More informationPierre Legault CEO June 2, 2014
April 2012 Pierre Legault CEO June 2, 2014 Forward Looking Statements This presentation includes statements that are, or may be deemed, forward-looking statements. In some cases, these forward-looking
More informationMay 10, 2016 Q & Business Update
May 10, 2016 Q1 2016 Thank Financial you Results & Business Update Q1 2016 Financial Results Prepared Remarks Q1 Update Tom Hughes, Ph.D., Chief Executive Officer Clinical Update Dennis Kim, M.D., Chief
More informationCreating and developing innovative therapies. Deborah Rathjen CEO & Managing Director
Creating and developing innovative therapies Deborah Rathjen CEO & Managing Director Safe Harbor Statement Factors Affecting Future Performance This presentation contains "forward-looking" statements within
More informationBayer and Loxo Oncology to develop and commercialize two novel oncology therapies selectively targeting genetic drivers of cancer
Investor News Not intended for U.S. and UK Media Bayer AG Investor Relations 51368 Leverkusen Germany www.investor.bayer.com Bayer and Loxo Oncology to develop and commercialize two novel oncology therapies
More informationQ3 18 Earnings Supplemental Slides
(Nasdaq: INSY) Q3 18 Earnings Supplemental Slides November 5, 2018 Safe-Harbor Statement This presentation contains both historical information and forward-looking statements. Forward-looking statements
More informationINVESTOR PRESENTATION
INVESTOR PRESENTATION May 2018 2 FORWARD-LOOKING INFORMATION The following presentation contains statements that are considered forward-looking information ( FLI ) within the meaning of securities regulation.
More informationPhotoCure ASA. Presentation. Results 1 Quarter 2004
PhotoCure ASA Presentation Results 1 Quarter 2004 7 th of May 2004 Progress towards sustained profitability Continued product roll out Metvix European sales continue to grow Final US approval for Actinic
More informationLeading R&D pipeline with proven technology. Partners. Injection and drop-based allergy immunotherapy products
ALK at a glance The leading allergy immunotherapy specialist 33% of global allergy immunotherapy market Leading R&D pipeline with proven technology Strategic partnerships to globalise SLIT- tablet portfolio
More informationBuilding a Premier Oncology Biotech
Corporate Deck Building a Premier Oncology Biotech Dr. Helen Torley, President and CEO November 2018 Forward-Looking Statements All of the statements in this presentation that are not statements of historical
More informationAmicus Establishes Gene Therapy Pipeline for Lysosomal Storage Disorders (LSDs) Conference Call and Webcast September 20, 2018
Amicus Establishes Gene Therapy Pipeline for Lysosomal Storage Disorders (LSDs) Conference Call and Webcast September 20, 2018 Introduction 2 Safe Harbor This presentation contains "forward-looking statements"
More informationYEAR END REPORT. September 2013 August Diamyd Medical AB (publ), Fiscal year 2013/2014
YEAR END REPORT September 2013 August 2014 Diamyd Medical AB (publ), Fiscal year 2013/2014 Reporting period, June 1, 2014 August 31, 2014 Net sales amounted to MSEK 0.2 (0,1) Loss before tax amounted to
More informationCrisis Investing: Profits From a Diabetes Drug About to Get Approved Crisis Investing: Profits From a Diabetes Drug About to Get Approved
Crisis Investing: Profits From a Diabetes Drug About to Get Approved A Special Research Report from Bret Jensen's Biotech Gems Lexicon Pharmaceuticals (Nasdaq: LXRX): tackling one of America s biggest
More informationTELECONFERENCE Q November 2015
TELECONFERENCE Q3 2015 4 November 2015 Company disclaimer This presentation contains forward-looking statements that provide our expectations or forecasts of future events such as new product introductions,
More information